Upadacitinib is an oral selective inhibitor of Janus associated kinase 1 (JAK-1) that is used in the therapy of moderate-to-severe rheumatoid arthritis. Upadacitinib has been associated with a low rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury although it may pose a risk for reactivation of hepatitis B in susceptible patients. It is grouped under the following drug class(es): Immunosuppressants, JAK inhibitors, Kinase inhibitors and Tyrosine Kinase Inhibitors. Its therapeutic use is listed as anti-inflammatories, antirheumatic agents and dermatologicals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Upadacitinib anhydrous and upadacitinibum. Its PubChem CID is 58557659.
Upadacitinib
| CAS No | 1310726-60-3 |
|---|---|
| Molecular Formula | C17H19F3N6O |
| Molecular Weight | 380.40 g/mol |
| Synonyms | (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Upadacitinib is an oral selective inhibitor of Janus associated kinase 1 (JAK-1) that is used in the therapy of moderate-to-severe rheumatoid arthritis.
The listed CAS number is 1310726-60-3.
The listed molecular formula is C17H19F3N6O.
The listed molecular weight is 380.40 g/mol.
(3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide.
The source lists Upadacitinib anhydrous and upadacitinibum.